116 related articles for article (PubMed ID: 19407488)
41. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease.
Artunc F; Risler T
Nephrol Dial Transplant; 2007 Oct; 22(10):2900-8. PubMed ID: 17556407
[TBL] [Abstract][Full Text] [Related]
42. Paraneoplastic hormones: parathyroid hormone-related protein (PTHrP) and erythropoietin (EPO) are related to vascular endothelial growth factor (VEGF) expression in clear cell renal cell carcinoma.
Feng CC; Ding GX; Song NH; Li X; Wu Z; Jiang HW; Ding Q
Tumour Biol; 2013 Dec; 34(6):3471-6. PubMed ID: 23780896
[TBL] [Abstract][Full Text] [Related]
43. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment.
Xie Z; Wu X; Qiu Q; Gong Y; Song Y; Gu Q; Li C
Curr Eye Res; 2007 Sep; 32(9):757-64. PubMed ID: 17882708
[TBL] [Abstract][Full Text] [Related]
44. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment.
Lisowska KA; Debska-Slizień A; Bryl E; Rutkowski B; Witkowski JM
Artif Organs; 2010 Aug; 34(8):654-62. PubMed ID: 20528849
[TBL] [Abstract][Full Text] [Related]
45. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma.
Li JF; Chu YW; Wang GM; Zhu TY; Rong RM; Hou J; Xu M
BJU Int; 2009 Feb; 103(3):399-405. PubMed ID: 19021626
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Tagscherer KE; Wagener N; Haferkamp A; Penzel R; Brauckhoff A; Hohenfellner M; Sykora J; Walczak H; Teh BT; Autschbach F; Herpel E; Schirmacher P; Roth W
Clin Cancer Res; 2009 Jan; 15(2):650-9. PubMed ID: 19147771
[TBL] [Abstract][Full Text] [Related]
47. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
Oz Atalay F; Aytac Vuruskan B; Vuruskan H
APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
[TBL] [Abstract][Full Text] [Related]
48. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Bergh A; Ljungberg B
Eur Urol; 2006 Dec; 50(6):1272-7. PubMed ID: 16814458
[TBL] [Abstract][Full Text] [Related]
49. Erythropoietin as an angiogenic factor in gastric carcinoma.
Ribatti D; Marzullo A; Nico B; Crivellato E; Ria R; Vacca A
Histopathology; 2003 Mar; 42(3):246-50. PubMed ID: 12605644
[TBL] [Abstract][Full Text] [Related]
50. Relationships of P53 and Bak with EPO and EPOR in human colorectal cancer.
Baltaziak M; Koda M; Wincewicz A; Sulkowska M; Kanczuga-Koda L; Sulkowski S
Anticancer Res; 2009 Oct; 29(10):4151-6. PubMed ID: 19846965
[TBL] [Abstract][Full Text] [Related]
51. Expression of erythropoietin and erythropoietin receptor in peritoneal endometriosis.
Matsuzaki S; Canis M; Yokomizo R; Yaegashi N; Bruhat MA; Okamura K
Hum Reprod; 2003 Jan; 18(1):152-6. PubMed ID: 12525458
[TBL] [Abstract][Full Text] [Related]
52. Endothelial function does not relate to haemoglobin or serum erythropoietin concentrations and these do not explain the gender difference in endothelial function in healthy middle-aged men and women.
Tilling L; Hunt J; Jiang B; Sanders TA; Clapp B; Chowienczyk P
Eur J Clin Invest; 2013 Mar; 43(3):225-30. PubMed ID: 23330826
[TBL] [Abstract][Full Text] [Related]
53. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis.
Leo C; Horn LC; Rauscher C; Hentschel B; Liebmann A; Hildebrandt G; Höckel M
Clin Cancer Res; 2006 Dec; 12(23):6894-900. PubMed ID: 17145806
[TBL] [Abstract][Full Text] [Related]
54. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
[TBL] [Abstract][Full Text] [Related]
55. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
[TBL] [Abstract][Full Text] [Related]
56. Erythropoietin immunolocalization in renal cell carcinoma.
Clark D; Kersting R; Rojiani AM
Mod Pathol; 1998 Jan; 11(1):24-8. PubMed ID: 9556419
[TBL] [Abstract][Full Text] [Related]
57. Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo.
Christensen B; Nellemann B; Jørgensen JO; Pedersen SB; Jessen N
Lipids Health Dis; 2016 Sep; 15(1):160. PubMed ID: 27640183
[TBL] [Abstract][Full Text] [Related]
58. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Vasko J; Ljungberg B
Clin Cancer Res; 2005 Feb; 11(3):1129-35. PubMed ID: 15709180
[TBL] [Abstract][Full Text] [Related]
59. Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation.
Sinnamon KT; Courtney AE; Maxwell AP; McNamee PT; Savage G; Fogarty DG
Nephrol Dial Transplant; 2007 Jul; 22(7):1969-73. PubMed ID: 17353209
[TBL] [Abstract][Full Text] [Related]
60. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients.
Gudbjartsson T; Hardarson S; Petursdottir V; Thoroddsen A; Magnusson J; Einarsson GV
Eur Urol; 2005 Oct; 48(4):593-600. PubMed ID: 15964127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
